EGFR and lung carcinoma: The development of BMs in lung cancer patients who received an anti-EGFR treatment may be due to the TKI effectively killing the cancer cells with the exon 19 deletion or the L858R mutation, but the effect of the TKI could be insufficient on the cells with uncommon mutation, therefore increasing the possibility of these cells contributing to BM development.